Evonik wants to improve its operational profit (EBITDA) by 2027 by 2027 compared to 2023 with the company’s conversion initiated.
Half of each half should contribute to growth and lower costs, said the special chemical company in Essen. The return on capital (Roce), which will in future be the central financial character for Evonik, should increase to 11 percent by then. CEO Christian Kullmann spoke of ambitious goals. “But we know the quality of our business and see additional opportunities, for example from economic stimulus programs in Germany and Europe,” he said on the occasion of the capital market day.
In 2024 Evonik had shown a capital interest of 7.1 percent, more than twice the value of 2023 (3.4 percent). In the reference year 2023, the EBITDA was 1.66 billion euros, last year it improved by a quarter to 2.07 billion euros.
Evonik wants to create the intended profit enhancement of 500 million euros through growth with the help of a higher utilization of new systems and new innovative products. Another 500 million euros are to bring various cost reduction programs and individual measures that the MDAX company has already initiated.
“By 2027 we will concentrate on implementing our growth, cost and portfolio capabilities, improving our financial indicators and further strengthening our balance sheet by reducing debt,” said CFO Maike Schuh. Against this background, acquisitions excluded them. However, Evonik opened up other options, added it and specifically called the possibility of a share buyback.
The EVONIK share in Xetra trading is at times 0.49 percent in the red of EUR 20.20.
Dow Jones